Core Viewpoint - The company, Huace Testing, emphasizes the accuracy and completeness of its quarterly report, ensuring no false records or misleading statements are present [2][3]. Financial Data Summary - The quarterly report has not been audited [3][5]. - The company confirms that there are no adjustments or restatements required for previous accounting data [3]. - There have been changes in the company's equity due to reasons such as new share issuance and stock buybacks [3]. - The company does not have any non-recurring profit and loss items that meet the definition of non-recurring gains and losses [4]. Shareholder Information - The company has provided details on the total number of ordinary shareholders and the top ten shareholders' holdings [4]. - There are no changes in the top ten shareholders due to securities lending activities [4]. Other Important Matters - The company has indicated that there are no other significant matters to report in this quarterly update [4].

Core Viewpoint - The company, 华测检测, reported steady revenue growth for 2024 and Q1 2025, demonstrating resilience as a comprehensive testing institution [1][2]. Group 1: Financial Performance - In 2024, the company achieved revenue of 6.08 billion yuan, a year-on-year increase of 8.6%, and a net profit attributable to shareholders of 921 million yuan, up 1.2% [1]. - For Q1 2025, revenue reached 1.287 billion yuan, reflecting an 8.0% year-on-year growth, with a net profit of 136 million yuan, increasing by 2.8% [1]. - The non-recurring net profit for 2024 was 860 million yuan, a 9.8% increase year-on-year [1]. Group 2: Business Segments - Life Sciences segment (environmental and food testing) generated 2.84 billion yuan, a 13.75% increase, driven by new growth points in marine environment and agricultural testing [2]. - Industrial Testing segment reported revenue of 1.20 billion yuan, up 10.32%, with improved gross margins due to business upgrades [2]. - Consumer Products Testing segment saw revenue of 988 million yuan, a modest increase of 0.88%, impacted by reclassification in medical device product lines [2]. - Trade Assurance segment achieved 764 million yuan in revenue, a 9.19% increase, maintaining competitive advantages in niche markets [2]. - Pharmaceutical segment revenue declined by 14.71% to 287 million yuan, affected by regulatory actions, although the company is optimistic about future growth in CMC research and medical devices [2]. Group 3: Profitability Metrics - The non-recurring net profit margin for 2024 was 14.14%, an increase of 0.16 percentage points year-on-year [3]. - The overall gross margin for 2024 was 49.5%, up 1.42 percentage points, indicating strong competitive advantages [3]. - The company faced asset impairment losses of 34 million yuan and credit impairment losses of 85 million yuan in 2024, attributed to certain subsidiaries [3]. Group 4: Q1 2025 Performance - In Q1 2025, the non-recurring performance grew by 11.0%, with a non-recurring net profit margin increasing by 0.27 percentage points [4]. - The gross margin for Q1 2025 was 46.3%, up 0.99 percentage points, while the expense ratio decreased by 0.56 percentage points [4]. - The company has been actively pursuing acquisitions, including entities in Taiwan and Greece, to enhance its service offerings [4]. Group 5: Future Outlook - Revenue projections for 2025-2027 are 6.521 billion yuan, 7.191 billion yuan, and 7.921 billion yuan, with year-on-year growth rates of 7.18%, 10.28%, and 10.15% respectively [4]. - Expected net profits for the same period are 1.014 billion yuan, 1.143 billion yuan, and 1.287 billion yuan, with growth rates of 10.1%, 12.6%, and 12.7% respectively [4]. - The company maintains a PE valuation of 19.2x, 17.0x, and 15.1x for the years 2025, 2026, and 2027 [4].

Investment Rating - The investment rating for the company is "Buy" and it is maintained [7]. Core Views - The company has demonstrated resilient growth with a revenue increase of 8.6% year-on-year, reaching 6.08 billion yuan in 2024. The net profit attributable to shareholders rose by 1.2% to 0.921 billion yuan, while the non-recurring net profit increased by 9.8% to 0.860 billion yuan [2][6]. - In Q1 2025, the company achieved a revenue of 1.287 billion yuan, reflecting an 8.0% year-on-year growth, with a net profit of 0.136 billion yuan, up 2.8% [2][6]. Summary by Sections Financial Performance - For 2024, the company reported a total revenue of 60.8 billion yuan, with a year-on-year growth of 8.6%. The net profit attributable to shareholders was 9.21 billion yuan, a 1.2% increase, and the non-recurring net profit was 8.60 billion yuan, up 9.8% [2][6]. - In Q1 2025, the company recorded a revenue of 12.87 billion yuan, an 8.0% increase year-on-year, with a net profit of 1.36 billion yuan, reflecting a 2.8% growth [2][6]. Business Segments - The revenue from the Life Sciences segment (including environmental and food testing) was 2.84 billion yuan, a 13.75% increase. The Industrial Testing segment generated 1.20 billion yuan, up 10.32%. The Consumer Products Testing segment saw revenue of 0.988 billion yuan, a modest increase of 0.88%. The Trade Assurance segment achieved 0.764 billion yuan, a 9.19% growth. However, the Medical and Pharmaceutical segment experienced a decline of 14.71%, with revenue of 0.287 billion yuan [6][10]. Profitability Metrics - The company’s non-recurring net profit margin for 2024 was 14.14%, a slight increase of 0.16 percentage points. The overall gross margin improved to 49.5%, up 1.42 percentage points, indicating strong competitive advantages and internal control capabilities [10]. - In Q1 2025, the gross margin was 46.3%, reflecting a year-on-year increase of 0.99 percentage points, while the non-recurring net profit margin improved by 0.27 percentage points [10]. Future Outlook - The company forecasts revenues of 65.21 billion yuan, 71.91 billion yuan, and 79.21 billion yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 7.18%, 10.28%, and 10.15%. The net profit attributable to shareholders is expected to reach 10.14 billion yuan, 11.43 billion yuan, and 12.87 billion yuan over the same period, with corresponding growth rates of 10.1%, 12.6%, and 12.7% [10].

Core Viewpoint - The company Huace Testing announced a cash dividend plan for the fiscal year 2024, proposing a distribution of 1 yuan per share (before tax), totaling approximately 167 million yuan, which represents 18.16% of its net profit [2]. Group 1: Dividend Distribution - The proposed cash dividend for 2024 is 1 yuan per share, with a total cash payout of 167 million yuan [2]. - This marks the 17th cumulative cash distribution since the company's listing [2]. - The dividend yield for 2024 is 0.78%, an increase from 0.55% in 2023 [2]. Group 2: Financial Performance - For the fiscal year 2024, the company reported total revenue of 6.084 billion yuan, reflecting a year-on-year growth of 8.55% [2]. - The net profit for the same period was 921 million yuan, showing a year-on-year increase of 1.19% [2]. - The basic earnings per share (EPS) is reported at 0.55 yuan, with a weighted average return on equity (ROE) of 14.07% [2]. Group 3: Market Activity - The stock experienced a net outflow of 26.28 million yuan in principal funds today, with a total net outflow of 53.89 million yuan over the past five days [3]. - The latest margin financing balance for the stock is 564 million yuan, which has increased by 45.23 million yuan, representing an 8.72% rise over the past five days [4]. Group 4: Industry Comparison - Among the 22 companies in the social services sector that announced their 2024 dividend plans, Huace Testing's cash payout ranks fifth, with the highest being 548 million yuan from Foreign Service Holdings [4]. - The cash payout of Huace Testing accounts for 18.16% of its net profit, which is relatively moderate compared to other companies in the sector [4].

Financial Performance - The company's operating revenue for 2024 reached ¥6,084,016,542.19, representing an increase of 8.55% compared to ¥5,604,624,525.83 in 2023[29]. - The net profit attributable to shareholders for 2024 was ¥921,073,108.56, a slight increase of 1.19% from ¥910,203,484.57 in 2023[29]. - The net profit after deducting non-recurring gains and losses for 2024 was ¥860,428,668.83, up by 9.79% from ¥783,729,247.84 in 2023[29]. - The company's cash flow from operating activities for 2024 was ¥1,062,899,936.83, a decrease of 5.30% compared to ¥1,122,394,756.87 in 2023[29]. - The total assets at the end of 2024 amounted to ¥9,452,604,079.86, reflecting an increase of 8.04% from ¥8,749,114,094.50 at the end of 2023[29]. - The net assets attributable to shareholders at the end of 2024 were ¥6,913,388,893.02, which is an increase of 11.41% from ¥6,205,345,102.90 at the end of 2023[29]. - The basic earnings per share for 2024 was ¥0.5500, a slight increase of 0.47% from ¥0.5474 in 2023[29]. - The weighted average return on equity for 2024 was 14.07%, down by 1.48 percentage points from 15.55% in 2023[29]. - The company reported a net profit of ¥132,541,651.89 in Q1 2024, with a total operating revenue of ¥1,191,912,757.30 for the same quarter[31]. - The company received government subsidies amounting to ¥50,415,470.31 in 2024, compared to ¥92,972,326.72 in 2023[35]. Investment and Growth Strategy - The company has invested in new laboratories across various sectors, including new energy, new materials, and artificial intelligence, to capture future growth opportunities[12]. - The company aims to enhance the operational efficiency of newly established laboratories to gradually release capacity and achieve steady revenue growth[12]. - The company is focusing on enhancing its technical capabilities and expanding its service offerings in response to the growing demand in emerging technology sectors such as AI and renewable energy[42]. - The company is committed to aligning its operations with international standards to enhance competitiveness in the global market[9]. - The company aims to align with national strategies for quality improvement and sustainable development, enhancing its service quality and brand image to boost market competitiveness[44]. - The company is committed to enhancing its market presence through strategic acquisitions and expanding its service offerings across various sectors[89]. Research and Development - In 2022, the company's R&D investment reached 529 million yuan, an increase of 11.99% year-on-year, accounting for 8.70% of total revenue[64]. - The company has developed several innovative technologies, including AI-based data analysis techniques that significantly enhance the efficiency and accuracy of data analysis[64]. - The company has established a research team for optical precision instruments, successfully developing customized testing equipment to meet new business demands[64]. - The company has developed an automated feeding device that significantly improves the efficiency of microbial experiment preprocessing, having obtained a utility model patent with application number 202421049057.6[116]. - The company has published national standards for fitness equipment aimed at the elderly, establishing itself as a leader in the silver economy sector[116]. Quality Control and Compliance - The company emphasizes the importance of maintaining credibility and brand integrity, implementing a comprehensive quality control system to ensure the accuracy and reliability of testing reports[5]. - The company has established a comprehensive quality management system based on ISO/IEC17025 and ISO/IEC17020 standards, ensuring accurate and reliable testing services[54]. - The company has implemented a vertical management system for quality, health, safety, and environment across its divisions to ensure compliance with regulations[6]. - The company has developed a comprehensive anti-corruption manual to uphold high ethical standards in its operations[7]. - The company has established a comprehensive internal control system in accordance with the Basic Norms for Enterprise Internal Control, effectively preventing operational risks and protecting investors' rights[174]. Market Trends and Industry Insights - The revenue of the inspection and testing industry in China was 467.01 billion, with a year-on-year increase of 9.22%, indicating a recovery in industry growth compared to 2022[39]. - The proportion of traditional inspection fields in total industry revenue decreased from 47.09% in 2016 to 38.32% in 2023, highlighting a shift towards emerging sectors[40]. - The inspection and testing industry is experiencing increased concentration, with larger institutions gaining competitive advantages and driving market consolidation[44]. - The company operates over 160 laboratories and 260 service networks across more than 10 countries and regions, providing over 4 million credible inspection and certification reports annually[45]. Employee Development and Training - The company achieved a total employee training duration of 246,005.80 hours, with an average training duration of 18.21 hours per employee[59]. - The company has a 100% employee training coverage rate, with significant participation in both offline and online training programs[59]. - The company launched the "Sunshine Program" to enhance the capabilities of young talents, with 147 participants and a total training duration of 4,629.20 hours[59]. - The number of R&D personnel increased to 2,163 in 2024, representing an 11.04% growth compared to 1,948 in 2023[119]. Corporate Governance and Management - The company has a board of directors consisting of 7 members, with 4 non-independent directors, complying with legal and regulatory requirements[168]. - The company has established a performance evaluation incentive system linking management compensation to business performance, ensuring transparency in the hiring of senior management[170]. - The company has a diverse board with members having over 30 years of experience in the TIC industry, including significant roles in SGS Group and other international firms[186]. - The total remuneration paid to the board of directors, supervisors, and senior management during the reporting period amounted to 17.92 million yuan[195]. Sustainability and ESG Initiatives - The company is recognized as an independent third-party certification body for green low-carbon and ESG services, focusing on sustainable development and carbon footprint certification[49]. - The company issued carbon neutrality certificates to over 700 enterprises, promoting low-carbon development and supporting national carbon reduction goals[81]. - The company achieved a Wind ESG AA rating, ranking first in the professional services sector among Chinese listed companies, showcasing its commitment to sustainable development[100]. - The company emphasizes long-term sustainable development through improved QHSE management and ESG practices, aiming for a balanced growth and shareholder return[147].

Financial Performance - The company's revenue for Q1 2025 was CNY 1,286,784,490.74, representing a 7.96% increase compared to CNY 1,191,912,757.30 in the same period last year[5] - Net profit attributable to shareholders was CNY 136,192,319.03, up 2.75% from CNY 132,541,651.89 year-on-year[5] - The basic earnings per share for Q1 2025 was CNY 0.0814, reflecting a 2.91% increase from CNY 0.0791 in the same period last year[5] - Total operating revenue for the current period reached ¥1,286,784,490.74, an increase of 7.9% compared to ¥1,191,912,757.30 in the previous period[23] - Net profit attributable to the parent company was ¥4,685,575,225.04, compared to ¥4,549,382,906.01 in the previous period, indicating an increase of 3.0%[22] - The company's operating profit for the current period is ¥146,061,106.11, compared to ¥139,634,679.89 in the previous period, reflecting an increase of approximately 3.1%[24] - The total comprehensive income for the current period is ¥134,967,722.90, compared to ¥123,329,956.58 in the previous period, representing an increase of approximately 9.3%[24] - The total profit for the current period is ¥144,802,427.69, compared to ¥138,938,950.37 in the previous period, marking an increase of approximately 4.0%[24] Cash Flow and Assets - The net cash flow from operating activities improved by 47.10%, reaching CNY -89,935,338.73 compared to CNY -170,020,188.80 in the previous year[5] - The net increase in cash and cash equivalents was CNY -164,588,409.76, an improvement of 55.15% from CNY -366,962,504.73 in the previous year[13] - Cash and cash equivalents fell to ¥718,537,308.77 from ¥882,727,579.22, a decrease of 18.6%[20] - Cash and cash equivalents at the end of the period stand at ¥685,721,797.02, down from ¥1,057,848,986.16, a decrease of about 35.2%[27] - Current assets decreased to ¥3,841,806,128.73 from ¥4,226,964,792.28, a decline of 9.1%[21] - The company's total assets decreased by 3.29% to CNY 9,141,331,356.67 from CNY 9,452,604,079.86 at the end of the previous year[5] - Total liabilities decreased to ¥1,866,454,758.32 from ¥2,291,750,399.16, a reduction of 18.6%[21] Shareholder Information - Total number of common shareholders at the end of the reporting period is 77,614[15] - The largest shareholder, Hong Kong Central Clearing, holds 15.49% of shares, totaling 260,651,571 shares[15] - Wan Feng, a domestic individual, holds 14.94% of shares, totaling 251,335,874 shares, with 188,501,905 shares under lock-up[15] - The top 10 shareholders collectively hold significant stakes, with the top three shareholders accounting for 32.52% of total shares[15] - The company has a total of 251,058,526 shares under lock-up, primarily held by executives[18] - No changes in the number of restricted shares during the reporting period[18] Investment Activities - The company reported a significant increase in investment cash inflows, which rose by 363.56% to CNY 671,482,547.56 compared to CNY 144,854,466.57 in the previous year[13] - The company experienced a 145.30% increase in investment cash outflows, totaling CNY 688,346,669.85, up from CNY 280,608,896.04 year-on-year[13] - The company reported cash inflows from investment activities of ¥671,482,547.56, significantly higher than ¥144,854,466.57 in the previous period[26] Expenses and Costs - Total operating costs amounted to ¥1,122,778,824.26, up from ¥1,058,291,701.16, reflecting a rise of 6.1%[23] - The company reported a decrease in financial expenses by 282.83%, amounting to CNY 3,178,177.31, primarily due to reduced foreign exchange gains[10] - The company reported a research and development expense of ¥104,560,678.41, up from ¥98,828,982.57, reflecting a growth of 5.0%[23] Strategic Developments - The company has not disclosed any new strategies or significant market expansions in the current report[19] - There are no updates on new product developments or technological advancements mentioned in the call[19] - The company has not reported any mergers or acquisitions in the current reporting period[19] - The report indicates that there are no significant changes in the financing or borrowing activities of the top shareholders[19] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[23]

Core Insights - The company reported a revenue of 1.287 billion yuan for the first quarter of 2025, representing a year-on-year growth of 7.96% [1] - The net profit for the same period was 136 million yuan, showing a year-on-year increase of 2.75% [1] Financial Performance - Revenue for Q1 2025: 1.287 billion yuan, up 7.96% year-on-year [1] - Net profit for Q1 2025: 136 million yuan, up 2.75% year-on-year [1]

Core Points - The CSI All Share Commercial Services and Commercial Goods Index reported a value of 6908.95 points, showing a decline of 7.36% over the past month, an increase of 9.09% over the past three months, and a year-to-date increase of 1.70% [1] - The index is categorized into 11 primary industries, 35 secondary industries, over 90 tertiary industries, and more than 200 quaternary industries, providing a comprehensive analysis tool for investors [1] Index Holdings - The top ten weighted stocks in the CSI All Share Commercial Services and Commercial Goods Index include: - Xiaogoods City (10.4%) - Dinglong Co., Ltd. (5.84%) - Huace Testing (5.22%) - Hainan Huatie (4.09%) - Chenguang Co., Ltd. (2.96%) - Liyuan Information (2.94%) - Juran Smart Home (2.69%) - Shannon Chip Creation (2.11%) - Runxin Technology (2.09%) - Yintang Smart Control (2.05%) [1] Market Distribution - The market distribution of the index holdings shows that the Shenzhen Stock Exchange accounts for 62.93%, the Shanghai Stock Exchange for 36.72%, and the Beijing Stock Exchange for 0.35% [2] - In terms of industry composition, the index holdings are divided as follows: - Other Commercial Services and Goods (34.83%) - Traders (33.34%) - Market Services (17.87%) - Office Services and Goods (10.58%) - Commercial Printing (3.38%) [2] Sample Adjustment - The index samples are adjusted biannually, with adjustments implemented on the next trading day following the second Friday of June and December each year [2] - Weight factors are adjusted in accordance with the sample changes, and any special events affecting a sample company's industry classification will lead to corresponding adjustments in the index [2]

导读： 第十八届中国科学仪器发展年会将于2025年5月11-13日在上海召开，本届年会共设1个大会主会场，2个高峰论坛（CMO高峰论坛与i100峰会），14个平 行分论坛，1个采购对接闭门座谈会。 特别提示 微信公众号机制调整，请点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 为促进中国科学仪器产业健康快速发展，搭建科学仪器行业"政、产、学、研、用、资、媒"等各方有效交流平台，"第十八届中国科学仪器发展 年会（ACCSI 2 0 2 5）"定于2 0 2 5年5月11 - 1 3日在上海富悦酒店（上海市松江区茸悦路2 0 8弄）召开。ACCSI 2 0 2 5 以"数智驱动·新质引领"为主 题，由仪器信息网(i n str ume n t. c om. c n )主办，上海市松江区人民政府为指导单位。 ACCSI 定 位 为 科 学 仪 器 行 业 高 级 别 产 业 峰 会 ， 至 今 已 成 功 举 办 1 7 届 ， 单 届 参 会 人 数 突 破 1 5 0 0 人 ， 被 誉 为 科 学 仪 器 行 业 的 " 达 沃 斯 论 坛 " 。 ACCSI力求 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：300012 证券简称：华测检测 公告编号：2025-011 特此公告！ 华测检测认证集团股份有限公司 董 事 会 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 华测检测认证集团股份有限公司（以下简称"公司"）2024年度报告将于2025年4月18日披露，为了让广 大投资者进一步了解公司2024年度经营情况和公司发展战略等相关问题，公司将于2025年4月18日（星 期五）下午15：00至17：00举行2024年度网上业绩说明会。本次业绩说明会将通过深圳证券交易所提供 的"互动易"平台采用网络远程的方式举行，投资者可登录"互动易"平台（http://irm.cninfo.com.cn），进 入"云访谈"栏目参与本次业绩说明会。 为充分尊重投资者、提升交流的针对性，本公司现就本次业绩说明会提前向投资者公开征集问题，广泛 听取投资者意见和建议。投资者可提前登录"互动易"平台（http://irm.cninfo.com.cn）"云访谈"栏目进入 公司2024年度业绩说明会页面进行提问。本公司将在本次年度业绩 ...